Semaglutide – how does the GLP-1 agonist work and what do the studies show?

What is semaglutide in brief?

Semaglutide is a synthetic analogue of GLP-1 (glucagon-like peptide-1) with a half-life of the order of weeks, designed to bind to albumin and therefore to be administered once a week in its dosage forms. The molecule mimics natural GLP-1 and activates GLP-1 receptors (GLP-1R) in the pancreas, the gastrointestinal tract and the brain.

---

🧠 How semaglutide works: 4 levels of action

1) Pancreas – “smart” insulin secretion

Semaglutide activates GLP-1R on β-cells → enhances insulin secretion, but only when glucose is elevated. At the same time, it suppresses glucagon from the α-cells. The result is more stable glucose homeostasis and a lower risk of hypoglycaemia compared with insulin secretagogues without a glucose-dependent mechanism.

2) Gastrointestinal system – a slower stomach, a greater feeling of satiety

Semaglutide preparations delay gastric emptying, which smooths the post-meal glucose peak and prolongs the feeling of satiety. This helps reduce energy intake.

3) Central nervous system – appetite control

GLP-1 receptors are present in the hypothalamus and in other brain regions involved in appetite/reward. Semaglutide activates the satiety neural pathways (POMC/CART) and inhibits the orexigenic signals (AgRP/NPY), further moderating the hedonic response to food. The effects may be caused directly or via the vagus nerve.

4) Pharmacological characteristics – why is it weekly?

Binding of the lipid side chain + albumin slows the clearance of semaglutide → t½ ≈ 1 week, a predictable profile and once-weekly dosing.

---

🧩 Mechanism → effect: quick card

Site	What does GLP-1 activation do?	Expected clinical signal*
Pancreas (β/α)	↑ insulin (glucose-dependent), ↓ glucagon	↓ fasting/post-meal glucose
Stomach/intestine	Delays emptying	Smaller portions, greater satiety
Brain	Suppresses appetite, affects reward	↓ calorie intake
Pharmaceutical form/dosage form	Albumin binding, t½ ~1 week	Once-weekly administration in the studies

* signals described for semaglutide preparations.

---

📊 What are the results in published studies?

• STEP-1 (NEJM, 68 weeks): −14.9% mean weight reduction with 2.4 mg/week + lifestyle change versus −2.4% with placebo; ≥10% weight loss in 69% versus 12%.

• STEP-5 (2 years): improvements in weight, waist, HbA1c and blood pressure were maintained for up to 104 weeks.

 

---

❓ Why do GLP-1 agonists lead to weight loss?

The combination of central control of appetite + slower gastric emptying reduces overall calorie intake. The simultaneous improvement in glucose control reduces hyperinsulinaemia and feelings of hunger after abrupt glycaemic fluctuations. Some reviews also discuss secondary effects on lipid metabolism and inflammation.

---

🧪 Why semaglutide is convenient in research (pharmaceutical profile)

• Predictable pharmacokinetics: long t½, linear exposure, steady concentration with weekly administration.

• Albumin binding: prolongs circulation and reduces clearance.
  
  

---

⚠️ Adverse events

Most common: nausea, vomiting, diarrhoea/constipation, sometimes a transiently increased heart rate; rare symptoms: pancreatitis, etc. Decisions about treatment fall exclusively within the remit of a healthcare professional and in accordance with the approved product information.

---

📚 Sources

• StatPearls: Semaglutide – mechanism and class effect.

• NEJM STEP-1 and editorial – main results at 68 weeks.

• A systematic review of the pharmacokinetic profile of semaglutide.

• Review in Signal Transduction and Targeted Therapy on GLP-1R mechanisms.

• Review: GLP-1 pathways in the brain and appetite control.

• Nature Medicine (STEP-5): maintenance of results for up to 104 weeks.

• FDA clinical pharmacology (albumin binding, t½).

---

✅ Conclusion

We believe you have gained a deep understanding of how semaglutide activates GLP-1 receptors in the pancreas, the stomach and the brain, leading to stabilisation of blood sugar, an increased feeling of satiety and weight loss. This multi-faceted action, combined with the predictable pharmacokinetic profile of weekly dosing, explains many of the results of published studies - such as a mean weight reduction of −14.9% at 68 weeks (STEP-1) and maintenance of the effect up to 104 weeks (STEP-5). For researchers, this provides a platform for studying a wide range of metabolic, neurological and endocrine interactions.